Received Feb 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | 944917 | SC / LA |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | X026222 | SC / LA |
After administration of MMR vaccine subcutaneous to the left upper arm, noticed the MMR vaccine had been reconstituted with the HEPLISAV-B vaccine instead of the sterile diluent. Subcutaneous injection was given at 11:30 AM. At 11:45 AM began c/o feeling flushed, slight blurry vision, rash noticed on bilateral sides of neck and on upper right scapula. Denied any symptoms of Anaphylaxis. 11:56 AM VS: BP 151/95 Pulse 75 Resp 16 O2 sat 98%. 12:05 PM Diphenhydramine 50 mg IM. 1225 rash and flushing has disappeared. Pt is feeling drowsy from the Benadryl injection. VSS. Monitored pt until daughter came to clinic to take her home. Pt denies any symptoms upon leaving with the exception of tiredness. Pt ambulated with assistance of RN to daughter's vehicle. Advised pt and daughter if patient were to experience any anaphylactic symptoms such as difficulty breathing, lip or tongue swelling or any other emergent conditions to report to the nearest emergency room for evaluation. Pt vitals upon clinic discharge at 1405 were: BP 134/83 heart rate 78, respirations 16, 02 sat 98%.
None
None
None
NKA
NONE